Endogenous  ||| S:0 E:11 ||| JJ
cardioprotective  ||| S:11 E:28 ||| JJ
mechanisms  ||| S:28 E:39 ||| NNS
-  ||| S:39 E:41 ||| :
what  ||| S:41 E:46 ||| WP
is  ||| S:46 E:49 ||| VBZ
it  ||| S:49 E:52 ||| PRP
about  ||| S:52 E:58 ||| RB
and  ||| S:58 E:62 ||| CC
how  ||| S:62 E:66 ||| WRB
does  ||| S:66 E:71 ||| VBZ
it  ||| S:71 E:74 ||| PRP
work ||| S:74 E:78 ||| VBP
?  ||| S:78 E:80 ||| .
Reperfusion  ||| S:80 E:92 ||| JJ
therapy  ||| S:92 E:100 ||| NN
is  ||| S:100 E:103 ||| VBZ
the  ||| S:103 E:107 ||| DT
primary  ||| S:107 E:115 ||| JJ
treatment  ||| S:115 E:125 ||| NN
for  ||| S:125 E:129 ||| IN
acute  ||| S:129 E:135 ||| JJ
myocardial  ||| S:135 E:146 ||| JJ
infarction ||| S:146 E:156 ||| NN
.  ||| S:156 E:158 ||| .
Its  ||| S:158 E:162 ||| PRP$
infarct-limiting  ||| S:162 E:179 ||| JJ
effectiveness  ||| S:179 E:193 ||| NN
is ||| S:193 E:195 ||| VBZ
,  ||| S:195 E:197 ||| ,
however ||| S:197 E:204 ||| RB
,  ||| S:204 E:206 ||| ,
limited  ||| S:206 E:214 ||| VBN
by  ||| S:214 E:217 ||| IN
so  ||| S:217 E:220 ||| RB
called  ||| S:220 E:227 ||| VBN
reperfusion-induced  ||| S:227 E:247 ||| JJ
myocardial  ||| S:247 E:258 ||| JJ
injury  ||| S:258 E:265 ||| NN
likely  ||| S:265 E:272 ||| RB
related  ||| S:272 E:280 ||| VBN
to  ||| S:280 E:283 ||| TO
reperfusion-mediated  ||| S:283 E:304 ||| JJ
opening  ||| S:304 E:312 ||| NN
of  ||| S:312 E:315 ||| IN
the  ||| S:315 E:319 ||| DT
mitochondrial  ||| S:319 E:333 ||| FW
permeability  ||| S:333 E:346 ||| FW
transition  ||| S:346 E:357 ||| FW
pore  ||| S:357 E:362 ||| FW
( ||| S:362 E:363 ||| -LRB-
mPTP ||| S:363 E:367 ||| NNP
) ||| S:367 E:368 ||| -RRB-
.  ||| S:368 E:370 ||| .
While  ||| S:370 E:376 ||| IN
pharmacologic  ||| S:376 E:390 ||| JJ
cardioprotection  ||| S:390 E:407 ||| NN
has  ||| S:407 E:411 ||| VBZ
proved  ||| S:411 E:418 ||| VBN
to  ||| S:418 E:421 ||| TO
effectively  ||| S:421 E:433 ||| RB
reduce  ||| S:433 E:440 ||| VB
infarct  ||| S:440 E:448 ||| JJ
size  ||| S:448 E:453 ||| NN
in  ||| S:453 E:456 ||| IN
the  ||| S:456 E:460 ||| DT
experimental  ||| S:460 E:473 ||| JJ
models  ||| S:473 E:480 ||| NNS
its  ||| S:480 E:484 ||| PRP$
clinical  ||| S:484 E:493 ||| JJ
usefulness  ||| S:493 E:504 ||| NN
is  ||| S:504 E:507 ||| VBZ
problematic ||| S:507 E:518 ||| JJ
.  ||| S:518 E:520 ||| .
In  ||| S:520 E:523 ||| IN
this  ||| S:523 E:528 ||| DT
context ||| S:528 E:535 ||| NN
,  ||| S:535 E:537 ||| ,
a  ||| S:537 E:539 ||| DT
clinical  ||| S:539 E:548 ||| JJ
exploitation  ||| S:548 E:561 ||| NN
of  ||| S:561 E:564 ||| IN
endogenous  ||| S:564 E:575 ||| JJ
cardioprotective  ||| S:575 E:592 ||| JJ
mechanisms ||| S:592 E:602 ||| NNS
,  ||| S:602 E:604 ||| ,
known  ||| S:604 E:610 ||| VBN
as  ||| S:610 E:613 ||| IN
ischaemic  ||| S:613 E:623 ||| JJ
preconditioning  ||| S:623 E:639 ||| NN
and  ||| S:639 E:643 ||| CC
ischaemic  ||| S:643 E:653 ||| JJ
postconditioning ||| S:653 E:669 ||| NN
,  ||| S:669 E:671 ||| ,
emerges  ||| S:671 E:679 ||| VBZ
as  ||| S:679 E:682 ||| IN
an  ||| S:682 E:685 ||| DT
attractive  ||| S:685 E:696 ||| JJ
therapeutic  ||| S:696 E:708 ||| JJ
alternative ||| S:708 E:719 ||| NN
.  ||| S:719 E:721 ||| .
This  ||| S:721 E:726 ||| DT
is  ||| S:726 E:729 ||| VBZ
particularly  ||| S:729 E:742 ||| RB
so  ||| S:742 E:745 ||| RB
because  ||| S:745 E:753 ||| IN
ischaemic  ||| S:753 E:763 ||| JJ
pre-  ||| S:763 E:768 ||| JJ
and  ||| S:768 E:772 ||| CC
post-conditionig  ||| S:772 E:789 ||| NNS
seem  ||| S:789 E:794 ||| VBP
to  ||| S:794 E:797 ||| TO
afford  ||| S:797 E:804 ||| VB
cardioprotection  ||| S:804 E:821 ||| VBN
by  ||| S:821 E:824 ||| IN
preventing  ||| S:824 E:835 ||| VBG
reperfusion-induced  ||| S:835 E:855 ||| JJ
deleterious  ||| S:855 E:867 ||| JJ
opening  ||| S:867 E:875 ||| NN
of  ||| S:875 E:878 ||| IN
mPTP ||| S:878 E:882 ||| JJ
.  ||| S:882 E:884 ||| .
